Clinically, ibrutinib rapidly induces lymphocytosis and lymph node shrinkage, a phenomenon common to BCR inhibitors, likely attributed to attenuation of BCR-dependent lymphoma–TME interactions12, 13, 14, 15. The gene discussed is BCR; the disease is lymphoma.